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1. Introduction 
Several hormones of gastrointestinal origin, 
including gastric inhibitory polypeptide (GIP), secre- 
tin, gastrin [1 ], cholecystokinin-pancreozymin [2] 
and pancreatic glucagon [3] stimulate the release of 
insulin and somatostatin from the isolated perfused 
pancreas. Vasoactive intestinal peptide (VIP), which 
has structural and biological similarities to GIP, 
secretin and pancreatic glucagon [4,5], has also been 
shown to stimulate insulin and glucagon release by 
the pancreas [6-8]. These studies of the effect of 
VIP on somatostatin release were, therefore, under- 
taken. 
2. Method 
The isolated canine pancreas preparation [9], as 
modified [3], was perfused using a semi-synthetic 
buffer medium in a non-recirculating system. The 
perfusate consisted of a Krebs-Ringer bicarbonate 
buffer with 4% Dextran T-70 (Pharmacia Fine 
Chemicals, Div. Pharmacia, Inc., Piscataway, NJ), 
0.2% bovine serum albumin, 5 mM each of pyruvate, 
fumarate and glutamate and 5.5 mM glucose. The 
preparation consisted of the isolated pancreas and 
10-12 cm adjoining duodenum. This was perfused 
via the coeliac artery at a constant flow rate of 
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18-20 ml/min and pressure between 20--40 mm 
Hg. The effluent of the pancreas was collected at 
1 min intervals into chilled tubes containing an EDTA/ 
benzamidine mixture (0.003 M/0.03 M)0.1 ml/10 ml 
effluent and stored at -20°C until assay. Insulin and 
glucagon were assayed as in [ 10,11 ], and somatostatin 
was assayed using the method in [12] and Arimura 
antiserum R101. 
Pure, natural VIP [13], generously provided by 
Dr S. I. Said, was infused (50 ng/ml) as a 9 min 
challenge on 1 or 2 occasions in each pancreas. An 
interval of 30 min hormone-free buffer perfusion 
preceded each challenge with VIP. In order to assess 
accurately the possibility of VIP-induced changes in 
flow, all effluent samples were weighed. There was 
no evidence of alterations in flow during these experi- 
ments. 
All experiments were analyzed using the Mann- 
Whitney [14] test for nonparametric data. Data are 
expressed as mean + SEM. 
3. Results and discussion 
Figure 1 represents a typical experiment in which 
50 ng/ml VIP was infused on 2 occasions in a single 
experiment, resulting in a 2-3-fold increase in insulin 
and somatostatin release on each occasion. The mean 
(-+ SEM) of the somatostatin a d insulin levels of all 
the experiments in which VIP was infused, a total of 
7 challenges in 4 experiments are summarized in
table 1. Peak response of both insulin + somatostatin 
occurred at 2 min or 3 min of the challenge. In all 
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Fig.1. The effect of VIP on immunoreactive nsulin (IRI), 
glucagon (IRG) and somatostatin (SLI) release from the 
isolated perfused og pancreas. 
instances a significant'increase in insulin and somato- 
statin was observed. The rise in glucagon was not 
statistically significant in any of the experiments. 
This demonstration f VIP-induced somatostatin 
release, together with its described insulin and gluca- 
gon stimulating properties, is compatible with the 
suggestion that VIP may play a role in modifying islet 
cell secretion [5-8].  Since VIP-contalning nerve 
fibers [15] and endocrine cells [16] have been 
observed in the pancreas, this effect could be a local 
one within the islet. If so, the high concentration f 
VIP used in this study may be compatible with intra- 
islet concentrations to which the hormone secreting 
cells are exposed. This D-cell response of VIP may 
also be responsible for the noted increase in somato- 
statin content of islets in the nontumorous area of 
human pancreas in cases of VIP-producing pancreatic 
tumors [5]. 
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Table 1 
The effect of VIP on immunoreactive somatostatin (SLI) and insulin concentrations a from the 
effluent of the isolated perfused og pancreas 
SLI (pg/ml) Insulin (vU/ml) 
Perfusate Buffer VIP Buffer b Buffer VIP Buffer b 
Expt. 1A 72± 6.5 114* 7.7 c 40 140± 9 213±46 170 
1B 95 ± 10.3 153 ± 6.7 c 370 193 * 13 232 ¢ 36 175 
2A 206± 11.7 734± 147 c 390 122± 6 247±45 156 
2B 325 + 34 744 ± 108 c 320 149 ± 9 232 ± 37 180 
3A 42± 1.6 65 ± 7.6 d 74 25 ± 0.2 39 ± 4.2 50 
4A 67 ± 3.2 118 ¢ 18 d 33 24 ± 1.5 44 ± 10.2 20 
4B 64 ± 3.5 109 ± 3.3 c 72 21 + 0.7 30 ± 5.3 23 
a Mean ± SEM of all samples measured during each of the 9 min perfusion periods 
For $LI, N = 9; for insulin,N = 5 
b The figures in this column represent the concentration f a single sample 9rain after cessation of 
the VIP stimulus C p < 0.005 
dp < 0.05 
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